Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mental health risk persists years after cancer diagnosis

2.

"We Caught It Early": Advantage or Disadvantage?

3.

A radiotheranostic approach designed to combat aggressive cancers

4.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

5.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot